Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Next Previous
Trial Profile

A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary) ; Nedaplatin; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 14 Feb 2023 Status changed from recruiting to completed.
  • 18 Oct 2020 Results published in the Investigational New Drugs
  • 31 May 2020 Results (n=53) assessing safety and efficacy of combination of endostar plus paclitaxel and nedaplatin recurrent or metastatic esophageal squamous cell carcinoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top